PDS Biotechnology Corporation (PDSB)Healthcare | Biotechnology | Princeton, United States | NasdaqCM
0.75 USD
-0.03
(-3.708%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 6:29 a.m. EDT
The investment case for PDS Biotechnology is currently defined by a stark disconnect between its deteriorating fundamentals and its speculative price action. The company is trapped in a multi-year structural decline, having lost over 99% of its value since 2016, with the last two years showing significant negative growth. Fundamentally, the picture is dire: the business is burning cash with negative free cash flow and operating cash flow, while returning negative equity to shareholders. The balance sheet is fragile, with debt significantly outweighing book value, and the forward P/E is negative due to losses. There is no dividend to provide income or a floor. Despite this, the options market shows a bizarre concentration of interest at the $2.50 strike price, suggesting traders are waiting for a specific catalyst to trigger a rally, yet there is almost no protective put buying to hedge against further downside. The recent price action confirms the bearish thesis, with the stock trading well below its 50-day and 200-day moving averages, reflecting a persistent lack of institutional support. While the analyst consensus targets a much higher price, these estimates appear disconnected from the reality of the company's financial burn and historical performance. For now, the security remains a high-risk speculative vehicle with no earnings power or income generation. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.104235 |
| AutoETS | 0.104560 |
| AutoARIMA | 0.104563 |
| AutoTheta | 0.284013 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 0.98 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.432 |
| Excess Kurtosis | -0.37 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 407.466 |
| Market Cap | 41,672,932 |
| Forward P/E | -1.60 |
| Beta | 1.58 |
| Website | https://www.pdsbiotech.com |
As of July 11, 2026, 6:29 a.m. EDT: Speculator positioning is extremely thin and skewed toward speculative long exposure. Call volume is concentrated entirely at the $2.50 strike across all expirations, representing a binary bet on a massive recovery rather than a directional trend. Put activity is negligible, indicating a lack of organized hedging or bearish conviction despite the severe price decline.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.3707317 |
| Address1 | 303A College Road East |
| All Time High | 517.4 |
| All Time Low | 0.507 |
| Ask | 0.949 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 376,950 |
| Average Daily Volume3 Month | 914,932 |
| Average Volume | 914,932 |
| Average Volume10Days | 376,950 |
| Beta | 1.582 |
| Bid | 0.5435 |
| Bid Size | 2 |
| Book Value | 0.07 |
| City | Princeton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.7452 |
| Current Ratio | 2.255 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 0.787 |
| Day Low | 0.725 |
| Debt To Equity | 407.466 |
| Display Name | PDS Biotechnology |
| Dividend Date | 1,552,867,200 |
| Earnings Call Timestamp End | 1,778,673,600 |
| Earnings Call Timestamp Start | 1,778,673,600 |
| Earnings Timestamp | 1,778,675,400 |
| Earnings Timestamp End | 1,786,624,200 |
| Earnings Timestamp Start | 1,786,624,200 |
| Ebitda | -28,898,770 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.239 |
| Enterprise Value | 35,794,544 |
| Eps Current Year | -0.49667 |
| Eps Forward | -0.46667 |
| Eps Trailing Twelve Months | -0.63 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.03324 |
| Fifty Day Average Change | -0.28803998 |
| Fifty Day Average Change Percent | -0.27877355 |
| Fifty Two Week Change Percent | -37.07317 |
| Fifty Two Week High | 1.55 |
| Fifty Two Week High Change | -0.8048 |
| Fifty Two Week High Change Percent | -0.5192258 |
| Fifty Two Week Low | 0.507 |
| Fifty Two Week Low Change | 0.23819995 |
| Fifty Two Week Low Change Percent | 0.46982235 |
| Fifty Two Week Range | 0.507 - 1.55 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,443,619,800,000 |
| Float Shares | 54,404,075 |
| Forward Eps | -0.46667 |
| Forward P E | -1.5968456 |
| Free Cashflow | -15,220,830 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 21 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0150999995 |
| Held Percent Institutions | 0.0917 |
| Implied Shares Outstanding | 55,921,806 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,552,867,200 |
| Last Split Factor | 1:20 |
| Long Business Summary | PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, Georgia Research Foundation, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey. |
| Long Name | PDS Biotechnology Corporation |
| Market | us_market |
| Market Cap | 41,672,932 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_53742727 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -33,355,594 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 41,605,823 |
| Number Of Analyst Opinions | 3 |
| Open | 0.7739 |
| Operating Cashflow | -23,091,402 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 800 208 3343 |
| Previous Close | 0.7739 |
| Price Eps Current Year | -1.5003926 |
| Price Hint | 4 |
| Price To Book | 10.645714 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.135 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0287 |
| Regular Market Change Percent | -3.70849 |
| Regular Market Day High | 0.787 |
| Regular Market Day Low | 0.725 |
| Regular Market Day Range | 0.725 - 0.787 |
| Regular Market Open | 0.7739 |
| Regular Market Previous Close | 0.7739 |
| Regular Market Price | 0.7452 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 322,405 |
| Return On Assets | -0.50493 |
| Return On Equity | -2.54091 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 55,921,806 |
| Shares Percent Shares Out | 0.024 |
| Shares Short | 1,340,328 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,759,233 |
| Short Name | PDS Biotechnology Corporation |
| Short Percent Of Float | 0.0249 |
| Short Ratio | 1.75 |
| Source Interval | 15 |
| State | NJ |
| Symbol | PDSB |
| Target High Price | 15.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 7.5 |
| Target Median Price | 4.5 |
| Total Cash | 21,660,496 |
| Total Cash Per Share | 0.388 |
| Total Debt | 15,861,214 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.63 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.907015 |
| Two Hundred Day Average Change | -0.16181505 |
| Two Hundred Day Average Change Percent | -0.17840393 |
| Type Disp | Equity |
| Volume | 322,405 |
| Website | https://www.pdsbiotech.com |
| Zip | 8,540 |